GlassScriptPhysician profile
Vinay Gulati
NPI 1275832370
$8,313.49
in general payments reported to CMS, 2019-2025
27 companies · $771 in 2025
The $771 reported for 2025 was more than what a typical Nuclear Cardiology provider received nationally (typical 2025 total: $434).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $116 · 2020: $983 · 2021: $2,169 · 2022: $2,093 · 2023: $877 · 2024: $1,305 · 2025: $771.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,783 · Education: $169.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,783.21 |
| Education | $168.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $1,553.76 | 2020-2024 | Uptravi, Opsumit |
| Amgen INC. | $982.02 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $673.72 | 2019-2025 | |
| Pfizer INC. | $653.86 | 2020-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $550.59 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $507.73 | 2020-2025 | Farxiga, Brilinta, Wainua |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $483.72 | 2019-2024 | Lifevest |
| Janssen Pharmaceuticals, INC | $477.60 | 2019-2022 | |
| Esperion Therapeutics, INC. | $393.45 | 2020-2025 | Nexletol |
| E.R. Squibb & Sons, L.L.C. | $382.15 | 2020-2025 | Camzyos, Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $321.36 | 2020-2025 | Jardiance |
| Novo Nordisk INC | $300.38 | 2021-2025 | Wegovy |
| Merck Sharp & Dohme LLC | $239.17 | 2021-2024 | Verquvo |
| Abbott Laboratories | $195.71 | 2021-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Assurity, Jot Dx |
| Medtronic, INC. | $123.21 | 2021-2024 | Linq II, Azure Xt Dr Mri Surescan |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $114.31 | 2022-2025 | Hillrom - Carnation Ambulatory Monitor |
| Regeneron Healthcare Solutions, INC. | $68.18 | 2020-2022 | |
| Kowa Pharmaceuticals America, INC. | $53.21 | 2020-2021 | |
| Kiniksa Pharmaceuticals, LTD. | $37.40 | 2022 | |
| Amryt Pharma Holdings LTD | $37.33 | 2021-2023 | Juxtapid |
| G Medical Diagnostic Services, INC. | $31.51 | 2022-2023 | Cardiac Monitoring Suite |
| Amarin Pharma, INC. | $29.97 | 2019-2020 | |
| Boston Scientific Corporation | $27.71 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $22.79 | 2023 | Inpefa |
| Kiniksa Pharmaceuticals International, Plc | $18.33 | 2024 | Arcalyst |
| Medicomp INC | $18.14 | 2025 | Telepatch Cardiac Monitor |
| Daiichi Sankyo INC. | $16.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vinay Gulati listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.